000			nab a22 7a 4500
999			_c17848 _d17848
003			PC17848
005			20240516130601.0
008			240516b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92452 _aSequeira Lopes Da Silva, José Tiago _eMedicina Interna
100			_9876 _aAguado García, José María _eEnfermedades Infecciosas
245	0	0	_aGalactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. _h[artículo]
260			_bThe Journal of infection, _c2016
300			_a72(6):738-44
500			_aFormato Vancouver: Fortún J, Martín Dávila P, Gómez Garcia de la Pedrosa E, Silva JT, García Rodríguez J, Benito D et al. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients. J Infect. 2016 Jun;72(6):738-44.
501			_aPMID: 27025205
504			_aContiene 28 referencias
520			_aBackground: The role of galactomannan (GM) in serum or bronchoalveolar lavage fluid (BALF) for the diagnosis of invasive pulmonary aspergillosis (IPA) has been extensively evaluated in hematological patients, however its performance in non-hematological patients is not well established. Methods: We performed a multicenter retrospective study in 3 university hospitals in Madrid, Spain between 2010 and 2014. The study population comprised patients with chronic obstructive pulmonary disease (COPD) and patients with immunosuppressive conditions in whom IPA was suspected and for whom BALF GM was available. Patients with hematological disorders were excluded. Results: A total of 188 patients (35 with COPD and 153 with immunosuppressive conditions) were analyzed, and 31 cases of IPA (proven or probable) were identified. The global sensitivity of BALF GM (optical density index [ODI] ≥ 1.0) was 77.4%; sensitivity was higher in patients with immunosuppressive conditions than in patients with COPD (81.8% vs 66.7%; p: 0.38). In COPD patients, the best performance was obtained for BALF GM (ODI ≥ 0.5), although sensitivity (88.9%) was similar to that of BALF fungal culture (88.9%). The sensitivity of GM in serum was very poor in both populations (36.4% and 11.6%, respectively). Conclusions: In the present series, the diagnostic performance of BALF GM was good for IPA in non-hematological patients, especially in patients with immunosuppressive conditions.
710			_96 _aServicio de Medicina Interna
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17848.pdf _ySolicitar documento
942			_2ddc _cART _n0